Common chromosomal fragile site FRA16D sequence:: identification of the FOR gene spanning FRA16D and homozygous deletions and translocation breakpoints in cancer cells

被引:242
作者
Ried, K
Finnis, M
Hobson, L
Mangelsdorf, M
Dayan, S
Nancarrow, JK
Woollatt, E
Kremmidiotis, G
Gardner, A
Venter, D
Baker, E
Richards, RI [1 ]
机构
[1] Womens & Childrens Hosp, Dept Cytogenet & Mol Genet, Adelaide, SA 5006, Australia
[2] Peter MacCallum Canc Inst, Melbourne, Vic 3002, Australia
[3] Univ Adelaide, Dept Pediat, Adelaide, SA 5000, Australia
[4] Univ Adelaide, Dept Genet, Adelaide, SA 5000, Australia
关键词
D O I
10.1093/hmg/9.11.1651
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Fluorescence in situ hybridization of a tile path of DNA subclones has previously enabled the cytogenetic definition of the minimal DNA sequence which spans the FRA16D common chromosomal fragile site, located at 16q23.2. Homozygous deletion of the FRA16D locus has been reported in adenocarcinomas of stomach, colon, lung and ovary. We have sequenced the 270 kb containing the FRA16D fragile site and the minimal homozygously deleted region in tumour cells. This sequence enabled localization of some of the tumour cell breakpoints to regions which contain AT-rich secondary structures similar to those associated with the FRA10B and FRA16B rare fragile sites. The FRA16D DNA sequence also led to the identification of an alternatively spliced gene, named FOR (fragile site FRA16D oxidoreductase), exons of which span both the fragile site and the minimal region of homozygous deletion. In addition, the complete DNA sequence of the FRA16D-containing FOR intron reveals no evidence of additional authentic transcripts. Alternatively spliced FOR transcripts (FOR I, FOR II and FOR III) encode proteins which share N-terminal WW domains and differ at their C-terminus, with FOR III having a truncated oxidoreductase domain. FRA16D-associated deletions selectively affect the FOR gene transcripts. Three out of five previously mapped translocation breakpoints in multiple myeloma are also located within the FOR gene. FOR is therefore the principle genetic target for DNA instability at 16q23.2 and perturbation of FOR function is likely to contribute to the biological consequences of DNA instability at FRA16D in cancer cells.
引用
收藏
页码:1651 / 1663
页数:13
相关论文
共 32 条
  • [11] The role of the FHIT/FRA3B locus in cancer
    Huebner, K
    Garrison, PN
    Barnes, LD
    Croce, CM
    [J]. ANNUAL REVIEW OF GENETICS, 1998, 32 : 7 - 31
  • [12] Sequence of the FRA3B common fragile region:: Implications for the mechanism of FHIT deletion
    Inoue, H
    Ishii, H
    Alder, H
    Snyder, E
    Druck, T
    Huebner, K
    Croce, CM
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (26) : 14584 - 14589
  • [13] JONES BD, 1994, DEV PLANT PATHOL, V3, P3
  • [14] ASSOCIATION OF A CHROMOSOME DELETION SYNDROME WITH A FRAGILE SITE WITHIN THE PROTOONCOGENE CBL2
    JONES, C
    PENNY, L
    MATTINA, T
    YU, S
    BAKER, E
    VOULLAIRE, L
    LANGDON, WY
    SUTHERLAND, GR
    RICHARDS, RI
    TUNNACLIFFE, A
    [J]. NATURE, 1995, 376 (6536) : 145 - 149
  • [15] TRINUCLEOTIDE REPEAT AMPLIFICATION AND HYPERMETHYLATION OF A CPG ISLAND IN FRAXE MENTAL-RETARDATION
    KNIGHT, SJL
    FLANNERY, AV
    HIRST, MC
    CAMPBELL, L
    CHRISTODOULOU, Z
    PHELPS, SR
    POINTON, J
    MIDDLETONPRICE, HR
    BARNICOAT, A
    PEMBREY, ME
    HOLLAND, J
    OOSTRA, BA
    BOBROW, M
    DAVIES, KE
    [J]. CELL, 1993, 74 (01) : 127 - 134
  • [16] Latil A, 1997, CANCER RES, V57, P1058
  • [17] Replication of a common fragile site, FRA3B, occurs late in S phase and is delayed further upon induction: implications for the mechanism of fragile site induction
    Le Beau, MM
    Rassool, FV
    Neilly, ME
    Espinosa, R
    Glover, TW
    Smith, DI
    McKeithan, TW
    [J]. HUMAN MOLECULAR GENETICS, 1998, 7 (04) : 755 - 761
  • [18] Le Beau MM, 1998, GENE CHROMOSOME CANC, V21, P281, DOI 10.1002/(SICI)1098-2264(199804)21:4<281::AID-GCC1>3.0.CO
  • [19] 2-V
  • [20] Mangelsdorf M, 2000, CANCER RES, V60, P1683